Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $25.93 in the prior trading day, Celldex Therapeutics Inc (NASDAQ: CLDX) closed at $26.34, up 1.58%. In other words, the price has increased by $1.58 from its previous closing price. On the day, 1.24 million shares were traded. CLDX stock price reached its highest trading level at $26.94 during the session, while it also had its lowest trading level at $25.79.
Ratios:
Our goal is to gain a better understanding of CLDX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.01 and its Current Ratio is at 13.01. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Mizuho on October 21, 2025, initiated with a Outperform rating and assigned the stock a target price of $48.
On October 13, 2025, Barclays started tracking the stock assigning a Underweight rating and target price of $25.
On April 28, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $64.Canaccord Genuity initiated its Buy rating on April 28, 2025, with a $64 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 04 ’25 when Jimenez Freddy A. sold 4,166 shares for $29.09 per share. The transaction valued at 121,210 led to the insider holds 30,796 shares of the business.
FREDDY A JIMENEZ bought 4,166 shares of CLDX for $121,210 on Dec 04 ’25. On Nov 13 ’25, another insider, Wright Richard M., who serves as the Former Officer of the company, sold 49,298 shares for $24.00 each. As a result, the insider received 1,183,177 and left with 20,833 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1750279040 and an Enterprise Value of 1169677056. For the stock, the TTM Price-to-Sale (P/S) ratio is 673.18 while its Price-to-Book (P/B) ratio in mrq is 2.92. Its current Enterprise Value per Revenue stands at 450.049 whereas that against EBITDA is -4.626.
Stock Price History:
The Beta on a monthly basis for CLDX is 1.24, which has changed by 0.13927948 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, CLDX has reached a high of $30.50, while it has fallen to a 52-week low of $14.40. The 50-Day Moving Average of the stock is 0.49%, while the 200-Day Moving Average is calculated to be 13.71%.
Shares Statistics:
The stock has traded on average 805.57K shares per day over the past 3-months and 832630 shares per day over the last 10 days, according to various share statistics. A total of 66.45M shares are outstanding, with a floating share count of 64.55M. Insiders hold about 2.86% of the company’s shares, while institutions hold 107.32% stake in the company. Shares short for CLDX as of 1767139200 were 8244450 with a Short Ratio of 10.23, compared to 1764288000 on 8675509. Therefore, it implies a Short% of Shares Outstanding of 8244450 and a Short% of Float of 14.66.
Earnings Estimates
A comprehensive evaluation of Celldex Therapeutics Inc (CLDX) is underway, with the input of 12.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$1.06, with high estimates of -$0.96 and low estimates of -$1.22.
Analysts are recommending an EPS of between -$3.24 and -$3.8 for the fiscal current year, implying an average EPS of -$3.59. EPS for the following year is -$4.42, with 10.0 analysts recommending between -$4.01 and -$4.89.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for CLDX’s current fiscal year. The highest revenue estimate was $7M, while the lowest revenue estimate was $1.4M, resulting in an average revenue estimate of $2.75M. In the same quarter a year ago, actual revenue was $7.02M
